Rare Pediatric Disease designation provides for the issuance of a rare pediatric disease priority review voucher following FDA approval. The voucher can be use for accelerated approval of a future application or it can be sold to a third party.
Shares are down 12% after hours in response to its $50M equity offering. Price, volume and terms have yet to be announced.
Now read: Sinking Sarepta »
Try Seeking Alpha PREMIUM for unlimited analysis on PRQR